Poor
Mostly Aligned
Patient Risk:
Medium
Summary
Several clinical statements align with label (indication, adult/pediatric age range, split-dose timing/dose count, notable GI side effects), but multiple claims are not supported by the provided prescribing information and the response includes significant non-label content (pricing/patent/coupons) that cannot be verified against the supplied label excerpts.
Category Scores
Accurate Statements
Clenpiq is a prescription medication used for colonoscopy preparation.
INDICATIONS AND USAGE: cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older.
Clenpiq is a dual-acting laxative solution that helps to cleanse the colon in preparation for a colonoscopy.
INDICATIONS AND USAGE (cleansing for colonoscopy). Clinical Pharmacology describes sodium picosulfate and magnesium oxide/citric acid components acting via colonic bacteria activation/peristalsis and osmotic effects.
Clenpiq is designed for adult use to achieve bowel cleansing.
INDICATIONS AND USAGE: cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older.
Clenpiq is typically taken in divided doses as directed by a healthcare professional.
DOSAGE AND ADMINISTRATION: Two doses are required for complete preparation as a Split-Dose regimen (first evening before; second next morning).
The exact timing and dosage schedule for Clenpiq are crucial for effective bowel cleansing and are outlined in the prescribing information.
DOSAGE AND ADMINISTRATION: Split-Dose regimen with specific timing (evening before; next morning approx 5 hours prior), clear-liquid instructions, and bottle/dose details.
Unsupported Statements
The average retail price for Clenpiq is around $72 for 175 ml of solution.
Not addressed in the provided FDA label excerpts.
Without insurance, the out-of-pocket cost for Clenpiq can be significantly higher.
Not addressed in the provided FDA label excerpts.
The cost of Clenpiq can vary depending on insurance coverage, pharmacy, and location.
Not addressed in the provided FDA label excerpts.
Patient assistance programs may be available to help reduce the cost of Clenpiq for eligible individuals.
Not addressed in the provided FDA label excerpts.
Discount coupons or savings cards may be offered by the manufacturer or available through online pharmacies for Clenpiq.
Not addressed in the provided FDA label excerpts.
Less common but more serious side effects can occur with Clenpiq.
The label excerpt does not support this generalization as phrased (it lists specific adverse reactions and warnings but does not categorize them as 'less common but more serious' in the provided text).
Common side effects associated with Clenpiq include nausea, vomiting, abdominal discomfort, and bloating.
The provided label excerpts explicitly list vomiting and abdominal pain, but do not explicitly list 'nausea' and 'bloating' as common adverse effects; 'abdominal discomfort' and 'bloating' are not directly supported by the provided text.
Specific patent expiry dates for Clenpiq can be found through resources that track pharmaceutical patents.
Not addressed in the provided FDA label excerpts.
Contradictions
Low
AI Statement
Clenpiq is designed for adult use to achieve bowel cleansing.
Label Reference
INDICATIONS AND USAGE indicates use in adults AND pediatric patients 9 years of age and older.
Low
AI Statement
Clenpiq is a dual-acting laxative solution that helps to cleanse the colon in preparation for a colonoscopy.
Label Reference
Label describes mechanisms involving sodium picosulfate and magnesium citrate/osmotic action, but it does not use the term 'dual-acting laxative' in the provided excerpts.
Important Omissions
Key safety contraindications (e.g., severe renal impairment with CrCl <30 mL/min; GI obstruction/ileus; bowel perforation; hypersensitivity).
Importance:
Moderate
Important warning/precaution content, including risk of serious fluid/electrolyte abnormalities, seizures, syncope, and colonic injury (ischemic colitis/ulceration) and related monitoring/management steps.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response largely omits contraindications and major warnings/precautions from the provided label excerpts, while adding multiple unsupported non-label claims (pricing/patents/coupons). Although it includes some dose-regimen-aligned timing/divided dosing concepts and some adverse-reaction mentions, the missing safety content could impair accurate labeling-based understanding.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts (especially pricing/patent/coupon claims and some adverse-effect specifics), and several material safety elements (contraindications/warnings) are omitted.
Suggested Improvement
Limit claims to what is supported in the prescribing information excerpts provided (indication, split-dose regimen details, and label-listed adverse reactions/warnings/contraindications). Remove or clearly separate non-label content such as pricing and patent information from label-based summaries.